Veru Inc. (VERU) shares experienced a dramatic surge on Thursday, closing at $4.23, an 88% gain, following the announcement of a clinical supply agreement with Novo Nordisk (NVO). The deal, disclosed in a Securities and Exchange Commission filing, involves Novo Nordisk providing Wegovy at no cost for Veru's Phase 2b PLATEAU obesity trial. This collaboration has been hailed by analysts as a significant external validation of Veru's approach, though lingering uncertainties, particularly a key termination clause, continue to cast a shadow.
The PLATEAU trial is designed to evaluate the combination of Veru's oral selective androgen receptor modulator, enobosarm, with Novo Nordisk's GLP-1 agonist Wegovy in older adults with obesity (BMI over 35). The study aims to enroll approximately 200 patients aged 65 and older, with interim results expected in the first quarter of 2027 and final top-line data anticipated in the fourth quarter of that year. Veru retains all global rights to enobosarm, but Novo Nordisk has secured a right of first negotiation should Veru seek to develop or market enobosarm in combination with any Novo GLP-1 drug.
Analysts have responded positively to the news. Oppenheimer's Leland Gershell described the deal as providing external validation for Veru's combination and oral maintenance strategy, maintaining an Outperform rating and a $24 price target. Canaccord Genuity echoed this sentiment, reiterating a Buy rating and a $25 target, calling the partnership a significant event that demonstrates enobosarm has captured the attention of a major player in the obesity space. Both firms noted that Veru's data appears compelling, though they acknowledged the inherent risks associated with clinical-stage biotechnology companies.
The market's reaction underscores the immense investor interest in the obesity treatment sector, currently dominated by Novo Nordisk and Eli Lilly (LLY). The GLP-1 market, which includes drugs like Wegovy and Ozempic, has seen intense competition and pricing pressure. Recent reports from Reuters highlighted strong demand for Novo Nordisk's oral weight-loss pill, but investors remain cautious about whether increased prescriptions can offset a potential price war as rivalry with Eli Lilly intensifies. Veru's strategy of developing enobosarm as an add-on therapy rather than a replacement for GLP-1 drugs positions it to capitalize on the expanding market for combination treatments.
Financially, Veru remains a clinical-stage company with no significant revenue. For its fiscal second quarter, the company reported a net loss of $2.7 million, or 12 cents per share, and had $27.6 million in cash, cash equivalents, and restricted cash as of March 31. The need for additional financing is a potential risk, especially given the lengthy timeline for the PLATEAU trial. CEO Mitchell Steiner has stated that the company is on track to present interim results in early 2027, but the path to commercialization remains distant.
Despite the enthusiasm, multiple risks persist. The PLATEAU study could fail to meet its primary endpoints, or regulatory authorities may require additional data before approval. Enrollment challenges are a possibility, and the company may need to raise capital to fund ongoing operations. Most notably, Novo Nordisk retains the right to terminate the supply agreement with just 60 days' notice, as stated in the SEC filing. This clause introduces a layer of uncertainty that could undermine the deal's value if Novo Nordisk decides to exit the partnership.
In pre-market trading on Friday, Veru shares were active, with Benzinga data showing the stock at $3.70 before the open. The volatility reflects the speculative nature of biotech investments, where a single partnership can drive significant price swings. For now, the Novo Nordisk deal provides a strong vote of confidence, but investors will be watching closely for trial results and any signs of instability in the agreement.
The broader obesity market continues to evolve rapidly, with both Novo Nordisk and Eli Lilly investing heavily in next-generation therapies. Veru's enobosarm, if successful, could offer a differentiated approach by preserving muscle mass during weight loss, a key concern for older adults. The PLATEAU trial's outcomes will be critical in determining whether Veru can carve out a niche in this competitive landscape.
